Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

DSpace Repository

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Author: Psyrri, A.; Fayette, J.; Harrington, K.; Gillison, M.; Ahn, M. -J.; Takahashi, S.; Weiss, J.; Machiels, J. -P.; Baxi, S.; Vasilyev, A.; Karpenko, A.; Dvorkin, M.; Hsieh, C. -Y.; Thungappa, S. C.; Segura, P. P.; Vynnychenko, I.; Haddad, R.; Kasper, S.; Mauz, P. -S.; Baker, V.; He, P.; Evans, B.; Wildsmith, S.; Olsson, R. F.; Yovine, A.; Kurland, J. F.; Morsli, N.; Seiwert, T. Y.
Tübinger Autor(en):
Mauz, Paul-Stefan
Published in: Annals of Oncology (2023), Bd. 34, H. 3, S. 262-274
Verlagsangabe: Elsevier
Language: English
Full text: http://dx.doi.org/10.1016/j.annonc.2022.12.008
ISSN: 0923-7534
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)